BTIG’s Timothy Chiang maintained a Buy rating on TEVA, with a price target of $77.
Buy The Weakness
Although the stock has declined 17 percent year to date, it has outperformed specialty pharma sector as a whole, which is down 34 percent. Chiang believes that this weakness offers an attractive buying opportunity.
“While “fear factors” continue to weigh on the group, including fear of earnings growth cuts due to some form of government drug price controls, we believe lawmakers may have little appetite for direct government negotiation of drug prices,” Chiang pointed out
The analyst also believes that the completion of the acquisition of the generic segment from Allergan plc Ordinary Shares AGN would drive the Teva Pharmaceutical up.
Acquisition Delayed
The company has earlier announced that there would be a delay in the completion of this acquisition, from early April to June 2016. “We believe the FTC’s review is taking longer as the generic pipelines for the two companies are evaluated by the FDA for potential overlap,” Chiang mentioned.
The analyst also stated that the EU regulators had recently approved the generics deal, and that the transaction was valued at $40.5 billion. Teva will be acquiring Allergan generic segment, which generated sales worth $6,375 million in 2015.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.